Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT®) was a randomised, double-blinded, multicentre trial that tested once-daily anticholinergic therapy (SPIRIVA® 18 µg via HandiHaler®) vs placebo in patients with COPD who were allowed to take all other types of COPD treatments (monotherapy or combination therapy, except other inhaled anticholinergics) for 4 years in 5,993 patients. This post-hoc analysis examined the number and frequency of COPD exacerbations from the UPLIFT® database. Time-to-event and number-of-event data were analysed for treated patients throughout the 4-year study duration. An additional post-hoc subgroup analysis comparing patients in each study group who were or were not receiving ICS at baseline was conducted.
Results from TIOSPIR®, a head-to-head trial in more than 17,000 COPD patients comparing the efficacy and safety of SPIRIVA® Respimat® 2.5 µg (once a day, two puffs) to SPIRIVA® 18 µg via HandiHaler®, powered to provide a precise estimate of mortality rates as well as COPD exacerbation rates.